A misleading piece of statistical rhetoric has appeared in a paper about an experimental antidepressant treatment. The study is published in the Journal of Affective Disorders. JAD is a respectable mid-ranked psychiatry journal – yet on this occasion they seem to have dropped the ball badly.
The study examined whether the drug armodafinil (Nuvigil) improved mood in people with bipolar disorder who were in a depressive episode. In a double-blind trial, 462 patients were randomized to treat